Abstract Context Insulinomas, although rare, are among the most common functional pancreatic neuroendocrine neoplasms (pNENs), causing debilitating and recurrent hypoglycemic episodes and severely affecting quality of life. Objective To evaluate endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as a novel and minimally invasive treatment for insulinomas. Design Retrospective cohort study between 2022 and 2025. Mean follow-up duration was 15.5 months. Setting A single tertiary care center experience. Patients We retrospectively identified patients with a suspicion of insulinomas (based on a positive fasting test and imaging) who underwent EUS-RFA. Lesions considered for RFA were biopsy-proven pNENs with a Ki67 index 10%, and 25 mm in size. Intervention All patients were hospitalized for 24 hours and EUS-RFA was conducted under general anesthesia using a dedicated EUS-RFA needle and under direct ultrasound guidance. Main outcome measures Clinical success (symptom improvement with a documented increase in blood glucose) and safety. Results 17 patients were identified and included. The mean age was 60.1 years and 53% were male. Normoglycemia was achieved after a single EUS-RFA session in 11 patients (64.7%), while 6 patients (35.3%) required a second EUS-RFA. The overall clinical success rate was 100% (n=17/17; 95% CI: 80.4—100.0%). Four adverse events were observed in 23 procedures (17.4%), two mild and two moderate (8.7%). Conclusions EUS-RFA appears to provide complete symptom resolution and demonstrates a favorable safety profile compared to conventional surgery. However, the long-term efficacy of EUS-RFA remains to be determined.
Kovacevic et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: